Genexine’s new drug candidate for chronic kidney disease-induced anemia, Efesa, has confirmed its efficacy through clinical trials. Genexine plans to confirm the drug’s competitiveness in the oversaturated anemia treatment market with its long-acting formulation.

According to the Financial Supervisory Service, Genexin recently announced that its CKD-induced anemia drug candidate Efesa (candidate name GX-E4) met its primary endpoint in a Phase 3 clinical trial.

Efesa comes in a long-acting formulation that utilizes Genexin's platform technology hyFc to extend the half-life of erythropoietin (EPO) in the body. Anemia is caused by decreased EPO production due to decreased kidney function, wh